TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma

Authors

  • Jessica Lee Foundation Medicine, Cambridge, MA
  • Arun Singh Department of Medical Oncology, University of California Los Angeles, Los Angeles, CA, USA
  • Siraj M. Ali Foundation Medicine, Cambridge, MA
  • Douglas I. Lin Beth Israel Deaconess Medical Center, Boston, MA
  • Samuel J. Klempner The Angeles Clinic and Research Institute, Los Angeles, CA ; Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA

DOI:

https://doi.org/10.5644/ama2006-124.248

Keywords:

Alk, Leiomyosarcoma, IMT, Kinase Fusion, C GP

Abstract

Objective. We report a female patient diagnosed with a leiomyosarcoma and who harbored a druggable target as identified by comprehensive genomic profiling in the course of clinical care.

Case Report. The patient progressed five years after curative intent surgery and adjuvant treatment. After failure of multiple lines of chemotherapy,she was enrolled in a trial of an ALK inhibitor based on comprehensive genomic profiling (CGP) identifying an TNS1-ALK fusion.

Conclusion. In this case, identification of the ALK kinase fusion permitted enrollment in a matched mechanism driven clinical trial after exhausting standard of care treatment options. CGP raises the possibility of uterine inflammatory myofibroblastic tumor as an alternative diagnosisto leiomyosarcoma, highlighting the complementary role of CGP beyond immunohistochemical analyses.

Downloads

Download data is not yet available.
Anna Bayerová (1853-1924)

Downloads

Published

2019-06-26

How to Cite

Lee, J., Singh, A., Ali, S. M., Lin, D. I., & Klempner, S. J. (2019). TNS1- ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma. Acta Medica Academica, 48(1), 116–120. https://doi.org/10.5644/ama2006-124.248

Issue

Vol. 48 No. 1 (2019): “Special Issue on Genomics in Hematology and Oncology Practice”

Section

Case Report